About Us | Contact

Dr. Andrew Thomas Colucci Investigator

Diagnostic Radiology Norwalk Hospital NPI1093078503
Update NPI

Open Payments

Note

The following payment details are based on a national transparency program known as the Sunshine Act that collects and publishes information about financial relationships between the health care industry (i.e. drug and device manufactures) and providers. These relationships may involve payment to providers for things such as research, speaking engagment, travel, gifts etc. Not all of these payment involve monetary compensations and may include batering of drugs or devices.

Total Payment Worth

$308,690.00
from 30 payments in the last 6 years

Total Cash or Cash Equivalent

$308,690.00
from 30 payments in the last 6 years

Total In-kind Items & Services

$0.00
from 0 payments in the last 6 years

Nature of Payments

Last 6 Years
Chart will render here...

Yearly Breakdown

Chart will render here...

Payment Details

Date Payment Type Form of Payment Item/Service Payment Amount
10/01/2021 General (Non-Research) Cash or cash equivalent Consulting Fee $19175.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 848721785
02/18/2021 General (Non-Research) Cash or cash equivalent Consulting Fee $8920.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 848721017
10/22/2021 General (Non-Research) Cash or cash equivalent Consulting Fee $6760.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 848717455
04/09/2021 General (Non-Research) Cash or cash equivalent Consulting Fee $8740.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 848694101
07/01/2021 General (Non-Research) Cash or cash equivalent Consulting Fee $7345.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 848676231
12/02/2021 General (Non-Research) Cash or cash equivalent Consulting Fee $3710.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 848670555
07/08/2021 General (Non-Research) Cash or cash equivalent Consulting Fee $8040.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 848610215
03/04/2021 General (Non-Research) Cash or cash equivalent Consulting Fee $53485.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 848573715
10/21/2021 General (Non-Research) Cash or cash equivalent Consulting Fee $4905.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 848550531
07/01/2021 General (Non-Research) Cash or cash equivalent Consulting Fee $12660.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 848526779
12/09/2021 General (Non-Research) Cash or cash equivalent Consulting Fee $8850.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 848312179
10/21/2021 General (Non-Research) Cash or cash equivalent Consulting Fee $3820.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 848309499
08/06/2021 General (Non-Research) Cash or cash equivalent Consulting Fee $4470.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 848308597
02/18/2021 General (Non-Research) Cash or cash equivalent Consulting Fee $14570.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 848308171
02/25/2021 General (Non-Research) Cash or cash equivalent Consulting Fee $65310.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 848308169
12/09/2021 Research Cash or cash equivalent Biological $770.00 Details
Payment from Regeneron Pharmaceuticals, Inc.
Paymment Research Study A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Clinical Trials Gov ID NCT03409614
Payment Record ID 793082021
12/02/2021 Research Cash or cash equivalent Biological $770.00 Details
Payment from Regeneron Pharmaceuticals, Inc.
Paymment Research Study A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Clinical Trials Gov ID NCT03409614
Payment Record ID 793082019
10/22/2021 Research Cash or cash equivalent Biological $1660.00 Details
Payment from Regeneron Pharmaceuticals, Inc.
Paymment Research Study A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Clinical Trials Gov ID NCT03409614
Payment Record ID 793082017
10/21/2021 Research Cash or cash equivalent Biological $650.00 Details
Payment from Regeneron Pharmaceuticals, Inc.
Paymment Research Study A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Clinical Trials Gov ID NCT03409614
Payment Record ID 793082015
10/21/2021 Research Cash or cash equivalent Biological $3040.00 Details
Payment from Regeneron Pharmaceuticals, Inc.
Paymment Research Study A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Clinical Trials Gov ID NCT03409614
Payment Record ID 793082013
07/28/2021 Research Cash or cash equivalent Biological $1300.00 Details
Payment from Regeneron Pharmaceuticals, Inc.
Paymment Research Study A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Clinical Trials Gov ID NCT03409614
Payment Record ID 793082011
07/08/2021 Research Cash or cash equivalent Biological $2230.00 Details
Payment from Regeneron Pharmaceuticals, Inc.
Paymment Research Study A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Clinical Trials Gov ID NCT03409614
Payment Record ID 793082009
06/17/2021 Research Cash or cash equivalent Biological $3420.00 Details
Payment from Regeneron Pharmaceuticals, Inc.
Paymment Research Study A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Clinical Trials Gov ID NCT03409614
Payment Record ID 793082007
04/29/2021 Research Cash or cash equivalent Biological $4720.00 Details
Payment from Regeneron Pharmaceuticals, Inc.
Paymment Research Study A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Clinical Trials Gov ID NCT03409614
Payment Record ID 793082005
04/09/2021 Research Cash or cash equivalent Biological $18730.00 Details
Payment from Regeneron Pharmaceuticals, Inc.
Paymment Research Study A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Clinical Trials Gov ID NCT03409614
Payment Record ID 793082003
03/11/2021 Research Cash or cash equivalent Biological $590.00 Details
Payment from Regeneron Pharmaceuticals, Inc.
Paymment Research Study A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Clinical Trials Gov ID NCT03409614
Payment Record ID 793082001
02/04/2021 Research Cash or cash equivalent Biological $1400.00 Details
Payment from Regeneron Pharmaceuticals, Inc.
Paymment Research Study A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Clinical Trials Gov ID NCT03409614
Payment Record ID 793081999
12/03/2020 General (Non-Research) Cash or cash equivalent Consulting Fee $6780.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 747840557
12/17/2020 General (Non-Research) Cash or cash equivalent Consulting Fee $27530.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 747840551
02/13/2020 General (Non-Research) Cash or cash equivalent Consulting Fee $4340.00 Details
Payment from Siemens Medical Solutions USA, Inc.
Payment Record ID 717208755
;